Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

New treatments targeting the Hedgehog pathway can help treat advanced skin cancer but may have side effects and their effectiveness in early stages is unknown.

Ruxolitinib helped regrow hair in a woman with a blood disorder and complete hair loss.

Recognizing and treating skin symptoms in essential thrombocythemia is crucial for patient quality of life.

Squaric acid dibutylester can cause severe skin reactions in people with allergies.

Ixekizumab has known and some unexpected side effects.

Rezpegaldesleukin shows promise for treating severe alopecia areata.

Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.

Intravaginal testosterone cream improves sexual satisfaction and reduces vaginal discomfort in postmenopausal women on breast cancer treatment without affecting hormone levels.

Betulinic acid can help treat hepatitis C by stopping virus replication.

ALRN-6924 may prevent hair loss caused by chemotherapy.

A rare type of skin cancer with mucosal involvement was partially treated but eventually relapsed.

Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.

A woman had a delayed allergic reaction to the blood thinner enoxaparin, treated with a steroid cream.

People with Behçet's disease can develop life-threatening lung artery aneurysms that may require surgery.

IVIG and dupilumab effectively improved symptoms in a child with Netherton syndrome.

The committee decided not to approve the drug due to low effectiveness and high risks.

Certain medications can cause serious side effects, so it's important to report them.

Baricitinib significantly regrows hair in severe alopecia areata patients.

Baricitinib works better in adolescents than adults for treating severe alopecia areata.

An 18-year-old girl with pemphigus vulgaris needed strong medication and careful treatment due to ineffective initial therapies and side effects.

Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.

Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.

Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.

Abemaciclib can cause skin, hair, and nail problems, leading some patients to stop using it.

Brodalumab effectively treated a man's severe hand and foot psoriasis.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

A new method improves betulin delivery in experiments, showing promise against certain tumors.